as a large drop of water floats in front of him on the Discovery.
Cohesion plays a bigger role in space. Following the advent of space stations that can be inhabited for long periods, exposure to weightlessness has been demonstrated to have some deleterious effects on human health. Humans are well-adapted to the physical conditions at the surface of the Earth. In response to an extended period of weightlessness, various physiological systems begin to change and atrophy. Though these changes are usually temporary, long-term health issues can result. The most common problem experienced by humans in the initial hours of weightlessness is known as
space adaptation syndrome (SAS), commonly referred to as space sickness. Symptoms of SAS include
nausea and
vomiting,
vertigo,
headaches,
lethargy, and overall malaise. The first case of SAS was reported by
cosmonaut Gherman Titov in 1961. Since then, roughly 45% of all people who have flown in space have suffered from this condition. The duration of space sickness varies, but in no case has it lasted for more than 72 hours, after which the body adjusts to the new environment. NASA jokingly measures SAS using the "Garn scale", named for
United States Senator Jake Garn, whose SAS during
STS-51-D was the worst on record. Accordingly, one "Garn" is equivalent to the most severe possible case of SAS. The most significant adverse effects of long-term weightlessness are
muscle atrophy (see
Reduced muscle mass, strength and performance in space for more information) and deterioration of the
skeleton, or
spaceflight osteopenia. such as cycling for example. Astronauts subject to long periods of weightlessness wear pants with elastic bands attached between waistband and cuffs to compress the leg bones and reduce osteopenia. Other significant effects include fluid redistribution (causing the "moon-face" appearance typical of pictures of astronauts in weightlessness), changes in the
cardiovascular system as blood pressures and flow velocities change in response to a lack of gravity, a decreased production of
red blood cells, balance disorders, and a weakening of the
immune system. Lesser symptoms include loss of body mass, nasal congestion, sleep disturbance, excess
flatulence, and puffiness of the face. These effects begin to reverse quickly upon return to the Earth. In addition, after long
space flight missions, astronauts may experience
vision changes. Such eyesight problems may be a major concern for future deep space flight missions, including a
crewed mission to the planet
Mars. Exposure to high levels of radiation may influence the development of atherosclerosis. Clots in the internal jugular vein have recently been detected inflight. On December 31, 2012, a
NASA-supported study reported that
human spaceflight may harm the brains of astronauts and accelerate the onset of
Alzheimer's disease. In October 2015, the
NASA Office of Inspector General issued a
health hazards report related to human spaceflight, including a
human mission to Mars.
Space motion sickness Space motion sickness (SMS) is thought to be a subtype of
motion sickness that plagues nearly half of all astronauts who venture into space. SMS, along with facial stuffiness from headward shifts of fluids, headaches, and back pain, is part of a broader complex of symptoms that comprise
space adaptation syndrome (SAS). SMS was first described in 1961 during the second orbit of the fourth crewed spaceflight when the cosmonaut
Gherman Titov aboard the
Vostok 2, described feeling disoriented with physical complaints mostly consistent with motion sickness. It is one of the most studied physiological problems of spaceflight but continues to pose a significant difficulty for many astronauts. In some instances, it can be so debilitating that astronauts must sit out from their scheduled occupational duties in space – including missing out on a spacewalk they have spent months training to perform. In most cases, however, astronauts will work through the symptoms even with degradation in their performance. Despite their experiences in some of the most rigorous and demanding physical maneuvers on earth, even the most seasoned astronauts may be affected by SMS, resulting in symptoms of severe nausea, projectile vomiting,
fatigue, malaise (feeling sick), and headache. Symptoms typically last anywhere from one to three days upon entering weightlessness, but may recur upon reentry to Earth's gravity or even shortly after landing. SMS differs from terrestrial motion sickness in that sweating and pallor are typically minimal or absent and gastrointestinal findings usually demonstrate absent bowel sounds indicating reduced
gastrointestinal motility. Even when the nausea and vomiting resolve, some central nervous system symptoms may persist which may degrade the astronaut's performance. Since then, their definition has been revised to include "...a symptom complex that develops as a result of exposure to real or apparent motion and is characterized by excessive drowsiness, lassitude, lethargy, mild depression, and reduced ability to focus on an assigned task." Together, these symptoms may pose a substantial threat (albeit temporary) to the astronaut who must remain attentive to life-and-death issues at all times. SMS is most commonly thought to be a disorder of the
vestibular system that occurs when sensory information from the visual system (sight) and the
proprioceptive system (posture, position of the body) conflicts with misperceived information from the semicircular canals and the otoliths within the inner ear. This is known as the 'neural mismatch theory' and was first suggested in 1975 by Reason and Brand. Alternatively, the fluid shift hypothesis suggests that weightlessness reduces the hydrostatic pressure on the lower body causing fluids to shift toward the head from the rest of the body. These fluid shifts are thought to increase cerebrospinal fluid pressure (causing backaches), intracranial pressure (causing headaches), and inner ear fluid pressure (causing vestibular dysfunction). Despite a multitude of studies searching for a solution to the problem of SMS, it remains an ongoing problem for space travel. Most non-pharmacological countermeasures such as training and other physical maneuvers have offered minimal benefit. Thornton and Bonato noted, "Pre- and inflight adaptive efforts, some of them mandatory and most of them onerous, have been, for the most part, operational failures." To date, the most common intervention is
promethazine, an injectable
antihistamine with
antiemetic properties, but sedation can be a problematic side effect. Other common pharmacological options include
metoclopramide, as well as oral and transdermal application of
scopolamine, but drowsiness and sedation are common side effects for these medications as well. Differences in mission duration, and the small sample size of astronauts participating in the same mission also adds to the variability to the
musculoskeletal disorders that are seen in space. In addition to muscle loss, microgravity leads to increased
bone resorption, decreased
bone mineral density, and increased fracture risks. Bone resorption leads to increased urinary levels of
calcium, which can subsequently lead to an increased risk of
nephrolithiasis. In the first two weeks that the muscles are unloaded from carrying the weight of the human frame during space flight, whole muscle atrophy begins. Postural muscles contain more slow fibers, and are more prone to atrophy than non-postural muscle groups. The use of
beta-2 adrenergic agonists to increase muscle mass, and the use of essential amino acids in conjunction with resistive exercises have been proposed as pharmacologic means of combating muscle atrophy in space. In a regular environment, gravity exerts a downward force, setting up a vertical hydrostatic gradient. When standing, some 'excess' fluid resides in vessels and tissues of the legs. In a micro-g environment, with the loss of a
hydrostatic gradient, some fluid quickly redistributes toward the chest and upper body, and may be moot sensed as 'overload' of circulating blood volume. In the micro-g environment, the newly sensed excess blood volume is adjusted by expelling excess fluid into tissues and cells (12-15% volume reduction) and red blood cells are adjusted downward to maintain a normal concentration (relative
anemia). These fluid shifts become more dangerous upon returning to a regular-gravity environment, as the body will attempt to adapt to the reintroduction of gravity. The reintroduction of gravity again will pull the fluid downward, but now there would be a deficit in both circulating fluid and red blood cells. The decrease in cardiac filling pressure and stroke volume during the orthostatic stress due to a decreased blood volume is what causes
orthostatic intolerance. Orthostatic intolerance can result in temporary loss of consciousness and posture, due to the lack of pressure and stroke volume. Some animal species have evolved physiological and anatomical features (such as high hydrostatic blood pressure and closer heart place to head) which enable them to counteract orthostatic blood pressure. More chronic orthostatic intolerance can result in additional symptoms such as nausea,
sleep problems, and other vasomotor symptoms as well. Many studies on the physiological effects of weightlessness on the cardiovascular system are done in parabolic flights. It is one of the only feasible options to combine with human experiments, making parabolic flights the only way to investigate the true effects of the micro-g environment on a body without traveling into space. Parabolic flight studies have provided a broad range of results regarding changes in the cardiovascular system in a micro-g environment. Parabolic flight studies have increased the understanding of orthostatic intolerance and decreased peripheral blood flow suffered by astronauts returning to Earth. Due to the loss of blood to pump, the heart can atrophy in a micro-g environment. A weakened heart can result in low blood volume, low blood pressure and affect the body's ability to send oxygen to the brain without the individual becoming dizzy.
Heart rhythm disturbances have also been seen among astronauts, but it is unclear whether this was a result of pre-existing conditions or an effect of the micro-g environment. One current countermeasure includes drinking a salt solution, which increases the viscosity of blood and subsequently increases blood pressure, which mitigates post-micro-g-environment orthostatic intolerance. Another countermeasure includes administration of
midodrine, which is a selective
alpha-1 adrenergic agonist. Midodrine produces arterial and venous constriction resulting in an increase in blood pressure by
baroreceptor reflexes.
Effects on non-human organisms Russian scientists have observed differences between cockroaches conceived in space and their terrestrial counterparts. The space-conceived cockroaches grew more quickly, and also grew up to be faster and tougher. Chicken eggs that are put in microgravity two days after fertilization appear not to develop properly, whereas eggs put in microgravity more than a week after fertilization develop normally. A 2006 Space Shuttle experiment found that
Salmonella typhimurium, a bacterium that can cause food poisoning, became more virulent when cultivated in space. On April 29, 2013, scientists in Rensselaer Polytechnic Institute, funded by NASA, reported that, during spaceflight on the International Space Station,
microbes seem to adapt to the space environment in ways "not observed on Earth" and in ways that "can lead to increases in growth and
virulence". Under certain test conditions, microbes have been observed to thrive in the near-weightlessness of space and to
survive in the vacuum of outer space. ==Commercial applications==